Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PYC Therapeutics Limited ( (AU:PYC) ) just unveiled an announcement.
PYC Therapeutics has announced the progression of its clinical trials for PYC-003, a drug candidate targeting Polycystic Kidney Disease (PKD). Following approval from the Safety Review Committee, the company will advance to Part B of the Single Ascending Dose study and escalate dosing in Part A. This milestone allows PYC to commence patient dosing and aligns with their timeline to initiate repeat dose studies by Q4 2025, marking significant progress in their efforts to address PKD.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a precision medicine company focused on developing treatments for genetic diseases with no available options. The company is engaged in clinical-stage drug development programs, including a candidate addressing Polycystic Kidney Disease (PKD).
Average Trading Volume: 580,671
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$746.6M
See more insights into PYC stock on TipRanks’ Stock Analysis page.